Tyche Wealth Partners LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 41.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 31,618 shares of the company’s stock after buying an additional 9,219 shares during the period. Johnson & Johnson makes up approximately 1.2% of Tyche Wealth Partners LLC’s holdings, making the stock its 18th biggest holding. Tyche Wealth Partners LLC’s holdings in Johnson & Johnson were worth $8,371,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Wellington Management Group LLP grew its holdings in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Deutsche Bank AG lifted its holdings in Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after buying an additional 1,225,676 shares in the last quarter. Fisher Asset Management LLC boosted its position in Johnson & Johnson by 11.5% in the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after buying an additional 1,530,070 shares during the period. Amundi lifted its holdings in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $1,967,399,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Analysts Set New Price Targets
Several analysts recently commented on the stock. Guggenheim restated a “buy” rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Sanford C. Bernstein set a $270.00 price objective on shares of Johnson & Johnson in a research report on Thursday, October 15th. Johnson Rice lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Weiss Ratings cut Johnson & Johnson from a “buy (b+)” rating to a “buy (b-)” rating in a research report on Friday, October 23rd. Finally, Royal Bank Of Canada cut their price target on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.
Read Our Latest Stock Report on JNJ
Insider Activity
In related news, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.16% of the company’s stock.
Recent Johnson & Johnson Headlines
Here are a few of the latest headlines about JNJ:
- Positive Sentiment: J&J submitted an FDA application to expand CAPLYTA’s use to manic or mixed episodes associated with bipolar I disorder. Two Phase 3 trials showed symptom improvement versus placebo; approval would add a potential fifth adult indication and broaden the drug’s commercial opportunity. Article: Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to talc in its baby powder, renewing concern about litigation exposure. Article: Louisiana Appeals Court Upholds Damages in Mesothelioma Case
- Negative Sentiment: Recent coverage also associated a prior decline in JNJ shares with insider selling, which can add near-term pressure on investor sentiment. Article: JNJ Stock Price Down Following Insider Selling
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ opened at $272.75 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business’s 50 day moving average price is $267.42 and its 200-day moving average price is $250.61. The firm has a market capitalization of $656.58 billion, a PE ratio of 41.33, a P/E/G ratio of 2.75 and a beta of 0.22. Johnson & Johnson has a 1 year low of $199.38 and a 1 year high of $290.25.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is presently 81.21%.
Johnson & Johnson Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Read More
- Five stocks we like better than Johnson & Johnson
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
